Klara Sonnie Hinrichsmeyer

Klara Sonnie Hinrichsmeyer

Auto-generated profile, based on publicly available information

Klara Sonnie Hinrichsmeyer

Pfizer Pharma GmbH, Berlin, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LRLisa Maria Riedmayr
Lisa Maria Riedmayr
KHKlara Sonnie Hinrichsmeyer
Klara Sonnie Hinrichsmeyer
STStefan Bernhard Thalhammer
Stefan Bernhard Thalhammer
DMDavid Manuel Mittas
David Manuel Mittas
NKNina Karguth
Nina Karguth
EBElvir Becirovic
Elvir Becirovic
Large genes including several CRISPR-Cas modules like gene activators (CRISPRa) require dual adeno-associated viral (AAV) vectors for an efficient in vivo delivery and expression. Current dual AAV vector approaches have important limitations, e.g., low reconstitution efficiency, production of alien proteins, or low flexibility in split site selection. Here, we present a dual AAV vector technology based on reconstitution via mRNA trans-splicing (REVeRT). REVeRT is flexible in split site selection and can efficiently reconstitute different split genes in numerous in vitro models, in human organoids, and in vivo. Furthermore, REVeRT can functionally reconstitute a CRISPRa module targeting genes in various mouse tissues and organs in single or multiplexed approaches upon different routes of administration. Finally, REVeRT enabled the reconstitution of full-length ABCA4 after intravitreal injection in a mouse model of Stargardt disease. Due to its flexibility and efficiency REVeRT harbors great potential for basic research and clinical applications.

7 February 2022 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
LRLisa M. Riedmayr
Lisa M. Riedmayr
KHKlara S. Hinrichsmeyer
Klara S. Hinrichsmeyer
NKNina Karguth
Nina Karguth
SBSybille Böhm
Sybille Böhm
VSVictoria Splith
Victoria Splith
EBElvir Becirovic
Elvir Becirovic

11 September 2024 in Pharmaceutical Medicine
Verified
Journal Article
Open access
PDF file
EFEmma Fröling
Emma Fröling
NRNeda Rajaeean
Neda Rajaeean
KHKlara Sonnie Hinrichsmeyer
Klara Sonnie Hinrichsmeyer
DDDina Domrös-Zoungrana
Dina Domrös-Zoungrana
JUJohannes Nico Urban
Johannes Nico Urban
CLChristian Lenz
Christian Lenz
The advent of artificial intelligence (AI) revolutionizes the ways of working in many areas of business and life science. In Medical Affairs (MA) departments of the pharmaceutical industry AI holds great potential for positively influencing the medical mission of identifying and addressing unmet medical needs and care gaps, and fostering solutions that improve the egalitarian and unbiased access of patients to treatments worldwide. Given the essential position of MA in corporate interactions with various healthcare stakeholders, AI offers broad possibilities to support strategic decision-making and to pioneer novel approaches in medical stakeholder interactions. By analyzing data derived from the healthcare environment and by streamlining operations in medical content generation, AI advances data-based prioritization and strategy execution. In this review, we discuss promising AI-based solutions in MA that support the effective use of heterogenous information from observations of the healthcare environment, the enhancement of medical education, and the analysis of real-world data. For a successful implementation of such solutions, specific considerations partly unique to healthcare must be taken care of, for example, transparency, data privacy, healthcare regulations, and in predictive applications, explainability.

23 October 2026 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
NSNils Schulze
Nils Schulze
MLMoritz Lehne
Moritz Lehne
ACAnja Cengia
Anja Cengia
KHKlara Sonnie Hinrichsmeyer
Klara Sonnie Hinrichsmeyer
AKAgnes Kisser
Agnes Kisser
CCCaoimhe Cawley
Caoimhe Cawley
Background: Sickle cell disease (SCD) is a rare inherited hemoglobinopathy associated with substantial morbidity and high healthcare needs. In Germany, population-based evidence on SCD epidemiology and real-world care patterns remains limited, despite increasing relevance in the context of migration and the introduction of nationwide newborn screening in 2021. Methods: We conducted a retrospective, non-interventional study using anonymized German statutory health insurance claims data from the InGef database (2015–2024). Patients with SCD were identified using ICD-10-GM codes D57.0, D57.1, D57.2, and D57.8 based on inpatient and confirmed outpatient diagnoses. Administrative prevalence was estimated using a carry-forward cohort approach, whereby SCD patients diagnosed in the current year and alive/observable in subsequent years were counted as prevalent. Administrative incidence was assessed in children aged < 6 years using the first recorded SCD diagnosis in claims data as the date of incidence. Analyses of patient characteristics, clinical outcomes, treatments and healthcare resource use (HCRU) were conducted cross-sectionally by calendar year, stratified by age group and sex. Results: Across 2015–2024, 1,019 individuals with SCD were identified. As might be expected using a carry forward cohort approach, annual prevalent counts increased from 225 (2015) to 864 (2024), and nationally extrapolated prevalence increased from 2.75 per 100,000 in 2015 to 10.50 per 100,000 in 2024. Median time to recorded diagnosis in children < 6 years decreased from 31 months (2015) to 11 months from 2021 onwards (2021–2024). In 2024, infections were the most frequently documented clinical outcome (34.5% [298/864]), followed by vaso‑occlusive crises (19.2% [166/864]) and mental health comorbidities (depression 19.1% [165/864]; anxiety 9.1% [79/864]). The proportions of patients with inpatient or outpatient visits, and with medication prescriptions (e.g. for antibiotics, antirheumatics, hydroxyurea), decreased over time. Conclusion: This claims-based analysis indicates increasing documented SCD prevalence in Germany. However, the extent to which prevalence increased due to a true increase in the general population, due to our carry-forward cohort approach, or due to other factors such as changes in coding practices or healthcare seeking behaviors, cannot be disentangled.We observed earlier recorded diagnosis timing in young children over time, alongside substantial age-dependent burden reflected in complications, mental health comorbidity, and healthcare utilization. Possible explanations for lower proportions of patients with inpatient/outpatient visits and medication prescriptions over time may include changes in disease awareness, patient management and/or healthcare seeking behaviours over time, and/or broader capture of patients with milder disease. Overall, our findings can inform healthcare planning and structured life-course–oriented SCD care pathways in Germany.

3 July 2026 in bioRxiv
Verified
Preprint
Open access
DMDavid M. Mittas
David M. Mittas
DODina Otify
Dina Otify
ZGZoran Gavrilov
Zoran Gavrilov
THThomas Heigl
Thomas Heigl
JSJan Suchomski
Jan Suchomski
EBElvir Becirovic
Elvir Becirovic
Mutations in MYO7A result in the most severe subtype of Usher syndrome, the leading genetic cause of deafblindness. The large size of MYO7A requires dual adeno-associated virus (AAV) vectors for gene transfer or alternative methods to treat retinal defects. Here, we evaluated two treatment approaches: i) Supplementation of the human MYO7A gene via dual mRNA trans-splicing AAVs, and ii) CRISPR/Cas-mediated activation of the related murine Myo7b gene. Upon MYO7A supplementation, the transgenic MYO7A transcript and protein were expressed and correctly localized in retinal pigment epithelial (RPE) and photoreceptors of mice, pigs, and human retinal organoids. In RPE- and photoreceptor-specific Myo7a knockout mice, we could restore MYO7A expression and localization of melanosomes in RPE cells to wild-type levels. Myo7b activation led to partial restoration of melanosome localization, and the localization of MYO7B protein was largely comparable to MYO7A. These findings indicate that both approaches are in principle suitable for the therapy of Usher syndrome.